 PARIS, FRANCE and CAMBRIDGE, MA ACCESSWIRE October 29, 2021 Biophytis SA NASDAQ:BPTSEuronext Growth Paris:ALBPS the Company or Biophytis, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today reports the restated financial statements as per the Companys previous announcement on October 7, 2021 for the periods ending December 31, 2019, December 31 2020, June 30 2020 and June 30 2021, with no impact on the Companys cash and cash equivalent as of June 30 2021. 1 Preliminary remarks Pursuant to the provisions of IAS 8, the Company determined following the review by and discussions with the Companys independent registered public accounting firm, that it is necessary to restate the Companys previously issued consolidated financial statements for the 2019 and 2020 financial years and for the first semester of the financial years 2020 and 2021, in order to make certain corrections required to reflect the proper accounting treatment of the Companys convertible notes. 